Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Management of Gastroparesis and GERD with Proton Pump Inhibitors

Introduction to Gastroparesis and GERD

  • The American Gastroenterological Association recommends that PPIs should not be routinely used to treat gastroparesis itself, but should be considered for managing concurrent gastroesophageal reflux disease (GERD) 1
  • Gastroparesis is a motility disorder characterized by delayed gastric emptying without mechanical obstruction, presenting primarily with nausea, vomiting, early satiety, and bloating 1
  • GERD is an acid-mediated disorder where delayed gastric emptying can worsen reflux symptoms by increasing gastric volume and pressure 2

Diagnosis and Treatment of Gastroparesis and GERD

  • The American College of Gastroenterology recommends initiating PPI therapy when gastroparesis patients present with troublesome heartburn, regurgitation, or non-cardiac chest pain 2, 3
  • Start with a 4-8 week trial of single-dose PPI taken 30-60 minutes before a meal 2, 3
  • If inadequate response after 4-8 weeks, increase to twice-daily dosing or switch to a more potent agent 2, 3
  • Once symptoms are controlled, taper to the lowest effective dose 2, 3

Important Clinical Considerations

  • PPIs do not directly improve gastric motility or emptying, and the dominant refractory symptoms in gastroparesis—nausea and vomiting—require escalation of prokinetic therapy, not acid suppression 1
  • Pursuing treatment based solely on delayed gastric emptying without addressing the dominant symptom may close the door on effective management options 1
  • The European Society of Gastrointestinal Motility recommends distinguishing gastroparesis from functional dyspepsia, as PPIs are highly effective for functional dyspepsia (FD), which can mimic gastroparesis 4

Long-Term PPI Monitoring and Adjunctive Therapy

  • If PPI therapy continues beyond 12 months in patients with unproven GERD, evaluate appropriateness and consider objective testing, including endoscopy with prolonged wireless pH monitoring off PPI 3, 5
  • Monitor for potential adverse effects including hypomagnesemia and vitamin B12 deficiency with chronic use 5
  • Extraesophageal symptoms (weakness, tingling, visual problems) are not typical GERD manifestations and warrant PPI discontinuation consideration 5
  • The American Gastroenterological Association recommends personalizing adjunctive pharmacotherapy to the specific symptom phenotype, including alginate antacids for breakthrough reflux symptoms, nighttime H2-receptor antagonists for nocturnal reflux symptoms, and baclofen for regurgitation-predominant symptoms 3, 6

Prokinetic Considerations

  • The American College of Gastroenterology recommends prokinetics (metoclopramide, domperidone where available) for gastroparesis motility symptoms 1, 7
  • In systemic sclerosis patients with gastroparesis and GERD, prokinetic drugs should be considered for symptomatic motility disturbances, and PPIs remain indicated for GERD and prevention of esophageal complications 7